Takeda's New Drug Shows Success in Two Pivotal Phase III Trials for Reducing Excessive Sleepiness; Bio-Thera Solutions' RMB 3.9 Billion Private Placement Approved

Amino Observation - Original Production by the Innovative Drug Team

Author | Huang Kai

/ 01 /

Capital Information

1) Zhongsheng Pharmaceutical's Net Profit in the First Half of the Year is Expected to Increase by 94.49%-140.25% Year-on-Year

On July 14, Zhongsheng Pharmaceutical announced that the estimated net profit attributable to shareholders of the listed company for the first half of 2025 will be RMB 170 million to RMB 210 million, representing a year-on-year increase of 94.49% to 140.25%.

2) Biokin's private placement approved, plans to raise no more than 3.9 billion yuan for R&D

Recently, Biokin announced that its refinancing application has been approved by the Shanghai Stock Exchange. The company plans to issue A-share stocks to specific investors and raise no more than 3.9 billion yuan (including this amount). After deducting issuance expenses, all actual proceeds will be used for innovative drug research and development projects.

3) Tonghua Dongbao Pharmaceutical Co., Ltd. Turns Profitable

On July 14, Tonghua Dongbao Pharmaceutical Co., Ltd. announced that the net profit attributable to shareholders of the listed company for the first half of 2025 is expected to be approximately 217.3467 million yuan, representing a turnaround from losses to profits compared with the same period last year.

/ 02 /

Pharmaceutical News

1) NUTSHELL Therapeutics Inc.'s NTS071 Tablet Granted Clinical Approval

On July 14, according to the CDE official website, NUTSHELL Therapeutics Inc.'s NTS071 tablet received clinical approval and is proposed to initiate research for the treatment of advanced solid tumors carrying the TP53 Y220C mutation.

2) Challenge Global First-Line Treatment: Shanghai Henlius Biotech, Inc. HLX22 Head-to-Head Phase III Clinical Trial Administers First Patient in the U.S.

On July 14, Shanghai Henlius Biotech, Inc. announced that the international multi-center Phase III study of HLX22, an innovative anti-HER2 monoclonal antibody, completed the first patient dosing in the United States. The study involves a head-to-head comparison with the first-line standard therapy (trastuzumab + chemotherapy ± pembrolizumab) and is intended for use in combination with trastuzumab and chemotherapy as a first-line treatment for HER2-positive advanced gastric cancer. Currently, there are no approved HER2 dual-targeted therapies globally for the treatment of HER2-positive gastric cancer.

/ 03 /

Overseas Pharmaceutical News

1) Breakthrough in New Drug for Refractory Hypertension: AstraZeneca's Potential Blockbuster Therapy Baxdrostat Succeeds in Clinical Trials

Recently, AstraZeneca announced that its experimental hypertension drug, Baxdrostat, effectively lowers blood pressure in patients with treatment-resistant or poorly controlled hypertension. In a late-stage clinical trial, patients were administered two different doses of Baxdrostat or a placebo daily. After 12 weeks, patients taking Baxdrostat showed a significant and clinically meaningful reduction in systolic blood pressure (which reflects the pressure when the heart pumps blood into the arteries).

2) Reduce Drowsiness! Takeda's Small Molecule New Drug Succeeds in Two Key Phase III Trials

On July 14, Takeda announced that its oral orexin receptor 2 (OX2R) selective agonist oveporexton (TAK-861) for the treatment of type 1 narcolepsy achieved all primary and secondary endpoints in the two pivotal Phase III FirstLight and RadiantLight studies.

PS: Welcome to scan the QR code below to add the WeChat ID of AminoGenius for communication.